Table 2.
Relationship between Pink1 expression and clinicopathologic features in patients with breast tumor.
| Pathological factors | Cases (n) | Pink1 expression (%) | p-value | |
|---|---|---|---|---|
| Weak/moderate | Strong | |||
| Malignant/benign | ||||
| Benign | 18 | 16 (88.9) | 2 (11.1) | 0.014* χ2 = 5.990 |
| Malignant | 150 | 89 (59.3) | 61 (40.7) | |
| Subtype of carcinoma | ||||
| Luminal A | 18 | 12 (66.7) | 6 (33.3) | 0.331 χ2 = 3.423 |
| Luminal B | 20 | 14 (70) | 6 (30) | |
| HER-2 | 24 | 17 (70.8) | 7 (29.2) | |
| Basal-like | 88 | 48 (54.5) | 40 (45.5) | |
| TNM staging | ||||
| 0–I | 42 | 30 (71.4) | 12 (28.6) | 0.092 χ2 = 2.831 |
| II–IV | 108 | 61 (56.5) | 47 (43.5) | |
| Lymph node metastasis | ||||
| − | 79 | 49 (62) | 30 (38) | 0.719 χ2 = 0.129 |
| + | 71 | 42 (59.2) | 29 (40.8) | |
| Grade | ||||
| I–II | 117 | 77 (65.8) | 40 (34.2) | 0.015* χ2 = 5.900 |
| III | 33 | 14 (42.4) | 19 (57.6) | |
| Age (years) | 150 | 52.96 ± 10.75 | 54.70 ± 11.16 | 0.330 t = −0.97 |
| Tumor size (cm) | 150 | 2.83 ± 1.23 | 2.63 ± 1.40 | 0.360 t = 0.920 |
HER-2: human epidermal growth factor receptor 2; TNM: tumor, nodes, and metastases.
*p < .05.